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Following an i.p. dose of 150mgkg
 1 5-fluorouracil (5-FU), drug uptake and metabolism over a 2-h period were studied by in vivo
19F
magnetic resonance spectroscopy (MRS) for the murine colon carcinoma lines C26-B (5-FU-insensitive; n¼11) and C26-10 (5-FU-
sensitive; n¼15) implanted s.c. in Balb/C mice. Time courses for tumour growth, intracellular levels of FdUMP, thymidylate synthase
(TS) activity, and 5-FU in RNA were also determined, and the effects of a 9.5-min period of carbogen breathing, starting 1min before
drug administration, on MRS-detected 5-FU metabolism and tumour growth curves were examined. Both tumour variants generated
MRS-detectable 5-FU nucleotides and showed similar initial growth inhibition after treatment. However, the growth rate of C26-B
tumours returned to normal, while the sensitive C26-10 tumours, which produced larger fluoronucleotide pools, still showed
moderate growth inhibition. Carbogen breathing did not significantly influence 5-FU uptake or fluoronucleotide production but did
significantly enhance growth inhibition in C26-10 tumours. While both tumour variants exhibited incorporation of 5-FU into RNA
and inhibition of TS via FdUMP, clearance of 5-FU from RNA and recovery of TS activity were greater for the insensitive C26-B line,
indicating that these processes, in addition to 5-FU uptake and metabolism, may be important determinants of drug sensitivity and
treatment response.
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Colorectal cancer is the third most common cancer in the Western
world. Fluoropyrimidine chemotherapy with agents such as 5-
fluorouracil (5-FU) is the main method of treatment, but is
effective in only a small percentage of patients. More insight into
the pharmacokinetics and intracellular metabolism of 5-FU in
tumour tissue is essential for a better understanding of the
variability of patient response and for the development of
improved therapy protocols.
The efficacy of 5-FU treatment depends primarily on tumour
uptake of 5-FU and its intracellular anabolic conversion to
cytotoxic fluoronucleotides.
19F magnetic resonance spectroscopy
(MRS) is a powerful method for assessing these aspects in vivo
since it allows the noninvasive detection and quantitation of 5-FU
and its metabolites in tumour during therapy. Such experiments
have been described for a number of animal models (Stevens et al,
1984; McSheehy et al, 1989; Koutcher et al, 1991; Sijens et al, 1991).
However, the clinically relevant problem of why various tumours
and patients exhibit widely differing sensitivities to 5-FU therapy
has, up to now, not been investigated in detail by this method.
The present study used
19F MRS at 4.23T to monitor in vivo in a
mouse model the uptake and metabolism of 5-FU in two variants
of the C26 murine colon carcinoma. These variants exhibit
different sensitivities to 5-FU as demonstrated by the finding that
a standard 5-FU treatment protocol cured all animals bearing the
sensitive C26-10 tumour, while the relatively insensitive C26-B
tumour showed only a two-fold increase in doubling time (van
Laar et al, 1996a). In addition to the MRS results, the effects of 5-
FU therapy on tumour growth in vivo and on biochemical
parameters determined in tumour extracts (e.g., incorporation of
5-FU into RNA; concentration and activity of the target enzyme
thymidylate synthase [TS]) were also examined. Furthermore, we
have studied the effect of a short carbogen breathing period on the
efficacy of 5-FU treatment for these two tumour variants since
carbogen breathing causes vasodilatation and, therefore, may
increase tumour perfusion and enhance delivery of 5-FU
( McSheehy et al, 1998; Howe et al, 1999; Kamm et al, 2000).
MATERIALS AND METHODS
Chemicals
5-FU was obtained from Teva (Mijdrecht, the Netherlands) as a
saline solution (50mgml
 1). Carbogen gas (95% O2/5% CO2) was
obtained from Hoekloos (Schiedam, the Netherlands).
Tumour model
Female Balb/C mice, 8–12 weeks old, were obtained from the
Central Animal Laboratory of our university. Two variants of the Received 3 April 2003; revised 28 May 2003; accepted 4 June 2003
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sC26 murine colon carcinoma were employed: C26-B, relatively
insensitive to 5-FU; C26-10, sensitive to 5-FU (van Laar et al,
1996a). Tumour tissue fragments (diameter: 3mm) were implanted
s.c. in the right flank of each mouse. The growing tumours
protruded from the body surface approximately as a half sphere,
and tumour volume (cm
3) was estimated from three orthogonal
diameter measurements (x, y, z) as volume¼0.5(xyz) (Peters et al,
1987). Eleven to 12 days after implantation, C26-B tumour volumes
were 0.6870.49cm
3 (mean and s.d., n¼22) while C26-10 tumour
volumes were 0.58 7 0.29cm
3 (n¼24). Mice were divided into
groups based on estimated tumour volume, and stratified
randomisation was carried out over the different treatment groups.
All experimental procedures in the following sections were
approved by the local ethics committee for the use of animals
according to the standards required by the UKCCR guidelines
(Workman et al, 1998).
Treatment
At days 11–12 after implantation (tumour volumes in the range
0.07–1.77cm
3), two groups of tumour-bearing mice (C26-B,
n¼11; C26-10, n¼15) were prepared for 5-FU therapy and
19F
MRS as follows. Each mouse was canulated i.p. under inhalation
anaesthesia using a mixture of enflurane (1.5%), oxygen (29.5%),
and nitrous oxide (69%) and mounted in the magnet bore of the
MR spectrometer. Core temperature was monitored with a rectal
temperature probe and maintained under anaesthesia at 371Cb y
means of a regulated warm water blanket. 5-fluorouracil was
administered i.p. as a 150mgkg
 1 bolus by injection of 0.1mlg
 1
body weight of 5-FU (1.5mgml
 1) in standard saline over a period
of 20s.
A second, analogous series of experiments including carbogen
breathing was performed with separate groups of mice bearing
C26-B (n¼11) and C26-10 (n¼9) tumours. The animals were
prepared for MRS as above, but 1min prior to 5-FU administration
the nitrous oxide and oxygen components of the anaesthesia were
replaced with carbogen (2lmin
 1). After administration of the 5-
FU bolus, carbogen breathing was continued for an additional
8.5min. The carbogen gas was then replaced by oxygen/nitrous
oxide for the remainder of the experiment.
The carbogen breathing time used in this study was chosen on
the basis of some known vascular responses. (i) After 1min of
carbogen breathing, the oxyhaemoglobin and deoxyhaemoglobin
concentrations in human glioma xenografts were found to be close
to their final steady-state values (van der Sanden et al, 1999). (ii)
Upon carbogen breathing, an increase in tumour pO2 has been
reported for both animals and patients; a maximum was reached in
patients after 1–6min (Guichard et al, 1994). (iii) In a clinical
study of head and neck tumours, the return to precarbogen levels
of oxygenation in tumours occurred within ca. 1min after the end
of carbogen exposure (Martin et al, 1993). (iv) In clinical
radiotherapeutic studies, carbogen breathing was applied 4min
before and continued during radiotherapy for a total exposure of
ca. 15min (Kaanders et al, 1995). Carbogen breathing reached its
maximal effect within ca. 10min.
In our study, the purpose of carbogen breathing was to induce a
short vasodilation and possibly improved uptake or trapping of 5-
FU in tumour after bolus injection. Therefore, carbogen breathing
was initiated 1min before 5-FU injection and continued for one
MR data acquisition block of 8.5min, for a total exposure of
9.5min.
Tumour growth
Tumour volume and body weight were monitored twice weekly for
4 weeks following day 0, the day of 5-FU therapy and MRS. For
each animal, the measured tumour volumes were divided by the
volume at day 0 to give the normalised volumes used in the
subsequent analysis. Antitumour activity was evaluated in terms of
the following parameters: AUC, the area under the tumour volume
growth curves; TD, the tumour doubling time, estimated as the
time required for tumours to double in volume after the beginning
of treatment; the growth-delay factor
GDF ¼ð TDtreated   TDcontrolÞ=TDcontrol ð1Þ
which provided a measure of the increase in doubling time caused
by treatment (van Laar et al, 1996a). Excluded from the analysis
were three mice that underwent histological examination and three
mice with less than three observations. In a previous study (van
Laar et al, 1996a), the average TD for untreated C26-10 and C26-B
tumours were 4.1 and 2.9 days, respectively, and these values were
used as historical control values TDcontrol. Toxic side effects were
evaluated as mean weight lost (WL) over the time period day 0 to
day 28 (as % of weight on day 0), the last day of the experiment, at
which point the mice were killed by cervical dislocation.
19F MR spectroscopy
19F MR spectra were measured at 169.457MHz using a 4.23-T
Oxford vertical-bore magnet (bore diameter¼75mm) and a SMIS
electronics console. A home-built, two-turn surface coil with an
internal diameter of 13mm, tuneable to
1Ho r
19F, was placed
around the s.c. tumour located in the right flank. The sensitive
volume of the coil was centred on the tumour tissue. Magnetic field
homogeneity was adjusted by shimming on the tissue H2O signal
to reach a line width of less than 70Hz (0.4ppm).
For
19F MRS, a simple pulse-acquire sequence was used with a
spectral width of 10kHz, a time domain of 4K points, a rectangular
radiofrequency pulse of length 20ms (ca. 701 flip angle at the centre
of the surface coil), and a repetition time TR¼0.5s. A flip angle
b¼701 is optimal in repetitive pulsing experiments for TR/
T1¼1.07, giving 496% of the maximum possible signal-to-noise
ratio. The
19F T1 values for 5-FU and its metabolites have not been
measured under our in vivo conditions, but are expected to lie in
the range of ca. 0.12–1.7s, measured at 1.5T (Li et al, 1998; Klomp
et al, 2003), and will depend not only on molecular weight, but also
to some extent on binding equilibria with proteins and local
concentrations of paramagnetic metal cations, for example. Thus,
the detected
19F signal intensity for a given small tissue voxel will
be proportional to
CmetB1Fsatsinb ð2Þ
where Cmet is the local metabolite concentration.
Fsat¼ð 1   E1Þ=ð1   E1cosbÞ;withE1 ¼ expð TR=T1Þð 3Þ
is the local saturation factor (depending on TR/T1 and the
position-dependent flip angle), and B1 (the local rf field strength
produced by the coil) is proportional to the local detection
sensitivity. The total signal will be the sum over all detectable voxel
signals and will depend on tumour size, metabolite concentration
distribution, as well as the spatial dependence of the saturation and
sensitivity factors. For a 701 flip angle, saturation factors (signal
intensity relative to the case TRbT1) will be 0.72–1.0 for TR/
T1¼1 (expected to apply for fluoronucleotides) or could be as low
as 0.35 for the extreme condition TR/T1¼0.3 (corresponding to
T1¼1.7s in our experiments).
Thus, in any given
19F spectrum, the relative signal areas for 5-
FU and its various metabolites will depend on the saturation
factors and may only crudely reflect their mean relative tissue
concentrations. However, we were interested in changes in signal
areas over time for a given metabolite and tumour (time course),
and signal vs time for a given metabolite should be roughly
proportional to an effective mean tissue concentration vs time if
saturation and sensitivity factors and the distribution of the
metabolite relative to the surface coil do not change dramatically.
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s1H decoupling was not used since the in vivo linewidths were
much larger than
3JHF (5Hz) for the fluorouracil moiety. The time-
domain
19F MR data were stored as sequential 8.5-min blocks
(1024 transients per free induction decay (FID)), beginning at the
moment of 5-FU injection and continuing over a period of 2h.
To check the localisation of the MR-sensitive volume, we used
the same experimental set-up to obtain
1H images and estimated
that nearby liver tissue represented less than 5% of the detected
volume. The absence of a significant contribution from liver or the
intraperitoneal volume to the
19F MR signals was further
confirmed by two
19F MRS measurements performed on animals
without tumour but treated as described above. In these cases, very
little signal from 5-FU or its metabolites was detected.
1H MR spectra were recorded at 180.130MHz before and after
19F MR acquisition with the rf coil still tuned to
19F (rf pulse length
20ms, rf power adjusted to give a 701 flip angle at the centre of the
coil, 64 transients, repetition time TR¼1s). These conditions are
similar to those used for
19F (optimal S/N for TR/T1¼1.07). The
resulting signal from tissue water will represent a complex sum of
product terms for each voxel, as described above for the
19F
measurements. Since the flip angle and TR/T1 parameters are
similar for the
19F and
1H measurements, the tissue volumes ‘seen’
by the two experiments should be similar (
1H T1 were not
measured but are expected to be in the range 0.5–2.5s, leading to
saturation factors in the range 0.33–1.0 for a 701 flip). Assuming
tissue water concentration is roughly constant, then the
1H signal
intensity should increase with tissue volume (tumour size) in the
same manner as the
19F signal will increase with tumour size if the
detected metabolite has a relatively uniform distribution with
constant mean concentration. Therefore, the
1H signal integral was
used to normalise the
19F signal integrals obtained from different
tumours and to provide a crude form of compensation for
differences in signal intensity caused by differences in tumour
volume alone. The
1H MR spectra were recorded before and 2h
after carbogen breathing to avoid effects of carbogen on the
amplitude or integral of the water
1H signal (relaxation effects due
to change in paramagnetic oxygen concentration).
Quantitative analysis of
19F MR spectra
For the presentation in Figure 1, two blocks of
19F time-domain
data (17-min acquisitions) were added and multiplied by an
exponential window function (line broadening of 20Hz) before
Fourier transformation to the frequency domain. The
19FM R
resonance frequency observed for 5-FU in vivo was defined as the
reference point for all chemical shift measurements (0.0ppm,
equivalent to ca.  93.5ppm relative to trifluoroacetate). Quanti-
tative analysis of the
19F and
1H MR spectra was performed by
fitting the time-domain signal using the software package MRUI
(van den Boogaart et al, 1995) and assuming Lorentzian line
shapes.
Relative tissue levels (in arbitrary units) for 5-FU (F), total
detectable anabolites (A, free fluoronucleotides not bound to or
incorporated in macromolecules), and total catabolites (C) were
estimated from the signal integrals for 5-FU, the spectral region
4.2–5.2ppm corresponding to FUMP, FdUMP, FUTP, etc., and the
region  16 to  20ppm corresponding to the major catabolites a-
fluoro-b-ureidopropionic acid (FUPA:  16.5ppm) and a-fluoro-
b-alanine (FBAL:  19.2ppm). All
19F signal integrals were
normalised by dividing by the mean value of the H2O signal
integral obtained from the two
1H reference spectra. The
normalised
19F MR signal integrals were then considered to
represent mean relative metabolite concentrations per unit volume
of tissue (averaged over the sensitive volume detected by the
surface coil) and, for a given metabolite, can be compared across
all animals and groups for all tumour volumes. This technique
assumes that the water
1H signal and the metabolite
19F signals
exhibit the same dependence for intensity vs tumour volume,
which should be a reasonable assumption if both tissue water and
5-FU metabolites have similar distributions, as discussed above.
No corrections were attempted for possible differences in
19F T1
and saturation factors for the various metabolites, which may
influence their relative signal integrals for a given tumour
spectrum. The tissue half-life (t1/2) of 5-FU was estimated from
the
19F MRS time course as the time required for 5-FU to decrease
from its maximum concentration to half that value.
Ex vivo determination of 5-FU, FdUMP, and 5-FU
incorporation into RNA
Two groups of mice bearing C26-B or C26-10 tumours received 5-
FU treatment (150mgkg
 1 bolus, i.p.) as described above for the
MRS and growth studies. Tumours were removed at various time
points after treatment and immediately frozen in liquid nitrogen.
Frozen tumours were pulverised (Peters et al, 1986), suspended in
three volumes of Tris-HCl buffer (pH 7.4, cooled on ice), and
immediately extracted with trichloroacetic acid (final concentra-
tion 5%). The supernatant was neutralised and stored until
analysis for FdUMP and 5-FU. The acid-insoluble precipitate was
used for the isolation of RNA and the measurement of 5-FU
incorporation into RNA.
FdUMP concentrations were measured by means of a dilution
assay based on the capacity of FdUMP in the tumour extract to
inhibit the binding of [6-
3H]FdUMP to thymidylate synthase from
Lactobacillus casei (van der Wilt et al, 1992). 5-Fluorouracil was
derivatised with penta-fluoro-benzylbromide (Peters et al, 2003)
and measured with gas chromatography coupled to mass spectro-
metry (GC–MS) using [
15N2]5-FU as an internal standard, as
described previously (Peters et al, 1993).
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Figure 1 Sequential
19F MR spectra (4.23T) obtained in vivo from a
subcutaneous C26-B ((A) 0.39cm
3) or C26-10 ((B) 0.45cm
3) murine
colon carcinoma in a Balb/C mouse following injection of a bolus i.p. dose
of 5-FU (150mgkg
 1) at time t¼0. Data acquisition was started
simultaneously with the 5-FU injection, and sequential 8.5-min data blocks
(FIDs) were stored. To improve the S/N for the presentation, each
spectrum shown was obtained by adding two successive 8.5-min
acquisitions (equivalent to 17min of time averaging) before Fourier
transformation. Peak labels: F¼unmetabolized 5-FU (chemical shift defined
as 0ppm); C¼the major catabolites FUPA ( 16.5ppm) and FBAL
( 19.2ppm); A¼a composite signal at ca. 5ppm representing the
overlapping peaks from all fluoronucleotides in oxy (FUMP, FUDP, FUTP,
FUDP-hexoses) and deoxy (FdUMP) forms.
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sIncorporation of 5-FU into RNA was determined using the RNA
isolated from the first precipitation step. Incubation with RNAse
(RNA breakdown), alkaline phosphatase (dephosphorylation), and
uridine phosphorylase (breakdown of fluorouridine to 5-FU)
resulted in the stepwise degradation of RNA to give 5-fluoro-
uridine-30-monophosphate (30-FUMP), 5-FUrd, and finally 5-FU,
which was analysed by GC–MS (Peters et al, 1995).
Evaluation of TS inhibition
Two assays were used to evaluate TS levels in the tumour extracts
described above. The ligand-binding assay using [6-
3H]FdUMP
gave a measure of the number of free FdUMP binding sites
available on TS after 5-FU treatment (van der Wilt et al, 1992). The
TS catalytic activity assay measured the rate of conversion of
[5-
3H]dUMP into dTMP and
3H2O (van Laar et al, 1996b).
Tumour volumes for treated and untreated control mice were in
the range 0.20–0.30cm
3. These tumours were generally chosen to
be smaller than those used for
19F MRS (where larger tumours
provide more MR signal) in order to avoid the development of an
unacceptably large tumour burden during the course of the
experiment when treatment was ineffective. However, in the
volume range tested, no significant differences in TS levels were
found, as long as the tumours were in the exponential growth
phase (van der Wilt et al, 1992; van Laar et al, 1996a, b).
Statistics
Statistical analyses were performed using the SAS software package
(SAS Institute, Cary, NC, USA). The parameters Cmax and AUC in
Table 1 have highly skewed distributions; therefore, median, min,
and max values are presented. For the two-way ANOVA
comparisons, which require distributions close to normality,
skewness was reduced by a log transformation of the Cmax data
and a square-root transformation of AUC. For Table 2 differences,
between mean values of parameters for different groups were
analysed by the unpaired Student’s t-test (two-sided, equal
variance). The two-sample Wilcoxon rank-sum test was used to
evaluate differences in t1/2 for 5-FU (Table 1) and the tumour
doubling time (TD, Table 3). Tumour growth curves following
treatment were analysed by a distribution-free analysis of variance
for repeated measurements (Koziol et al, 1981).
RESULTS
19F MRS of C26-B and C26-10 tumours following 5-FU
treatment
In Figure 1, representative time-course spectra (17-min time
averages) are shown for the two tumour types without carbogen
breathing. Up to four
19F MR signals were observed. The signal F at
0ppm on the chemical shift scale represents unmetabolised 5-FU;
it reached a maximum intensity within the interval 0–17min after
drug administration and decreased thereafter. The cytotoxic
anabolite pool derived from 5-FU (all fluoronucleotides such as
FdUMP, FUTP, and FUDP-hexoses) gave one composite peak (A)
at ca. 4.8ppm, which could be detected in the second or third
measurement block (8.5–25.5min) and increased to a maximum
plateau level after ca. 60–80min when 5-FU was no longer
detectable. Higher levels of anabolites (A) were generally observed
for the 5-FU-sensitive C26-10 tumours (Figure 1B). Catabolism of
5-FU (primarily in the liver) results initially in 5,6-dihydro-5-
fluorouracil (DHFU: not detected at  33.0ppm), which is rapidly
converted to the intermediate FUPA ( 16.5ppm) and finally to
FBAL ( 19.2ppm). These latter two catabolites appear to the left
and right of the label C in Figure 1.
The quantitative results from the MR experiments were
determined by analysis of the original data with 8.5-min time
Table 1 Median parameter values for 5-FU metabolism determined by in vivo
19F MRS of tumour-bearing
mice
a
Cmax
b AUC
c
Median (min, max) Median (min, max)
Metab. Tumour 5-FU 5-FU+carbogen 5-FU 5-FU+carbogen
5-FU C26-B 0.98 (0.44, 3.01) 0.78 (0.51, 1.61) 39 (15, 72) 34 (13, 77)
C26-10 0.78 (0.38, 2.95) 1 (0.45, 2.07) 27 (11, 80) 38 (17, 85)
P¼0.82 P¼0.63
Anab. C26-B 0.35 (0, 0.59) 0.36 (0.21, 0.50) 20 (0, 34) 25 (9, 35)
C26-10 0.65 (0.31, 2.81) 0.59 (0.45, 2.07) 50 (20, 190) 48 (33, 139)
P¼0.0004 P¼0.0001
Catab. C26-B 0.51 (0, 3.58) 0.36 (0, 0.76) 17 (0, 129) 14 (0, 31)
C26-10 0.35 (0, 3.56) 0.32 (0, 0.57) 13 (0, 96) 11 (0, 24)
P¼0.23 P¼0.36
5-FU t1/2 (min)
d
C26-B 25.5 (17, 51) 25.5 (8.5, 51)
C26-10 25.5 (8.5, 42.5) 34 (25.5, 34)
P¼0.51
aBalb-C mice bearing murine colon carcinoma (s.c.) were examined by
19F MRS following a bolus injection of 150mgkg
 1
5-FU (C26-B, n¼11; C26-10, n¼15) or following 5-FU treatment combined with 9.5min carbogen breathing (C26-B,
n¼11; C26-10; n¼9). Pharmacokinetic parameters were evaluated for 5-FU, the total NMR-detectable anabolite pool,
and the sum of the catabolites FUPA+FBAL. Two-way ANOVA was performed with transformed data (skewed
distributions, see Materials and Methods) and gave the P values shown for the main effect of tumour type; for the main
effect of carbogen, P40.05 was found in all cases.
bCmax¼mean of max tissue concentration in arbitrary relative units,
determined from
19F signal integrals normalised to constant tissue volume using the
1H signal from tissue water.
cAUC¼area under the concentration–time curve (from 0 to 119min), normalised to constant tissue volume.
dt1/2¼half-
life of 5-FU (time for decay from Cmax to 50% of Cmax).
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sresolution and are summarised in Table 1. For the fluoronucleotide
anabolites, both the maximum achieved concentration Cmax as well
as the AUC were significantly higher for the 5-FU-sensitive C26-10
tumour compared to C26-B (Po0.001), with or without carbogen
breathing. In contrast, Cmax and AUC for catabolites and 5-FU as
well as the half-life t1/2 of 5-FU were not significantly different for
the two tumour types (P40.2). Treatment with carbogen had no
effect on the mean values for the parameters of 5-FU metabolism
for either tumour variant (P40.05 in all cases), but resulted in a
significant reduction in the range of Cmax and AUC for catabolites.
Time course of metabolite concentrations and TS activity
as determined in tumour tissue extracts
Separate groups of tumour-bearing mice were given the same 5-FU
treatment as for the MRS studies (day 0¼11–12 days after
implantation), and tumours were excised at various times there-
after. Extracts of the excised tumour tissues were used to
determine the time courses for metabolites and TS enzyme activity
presented in Table 2. Although the mean FdUMP concentrations
over 2–48h were somewhat higher in the sensitive C26-10
tumours compared to the insensitive C26-B, these differences
were not statistically significant (P40.05). On the other hand, the
initial incorporation of 5-FU into RNA at day 2 or 3 after treatment
was about a factor of 3–4 lower in C26-10 compared to C26-B
(Po0.001 on day 3). However, at day 7 or 10 there was a more
rapid decrease in FU-RNA in the insensitive C26-B tumours to
values less than those observed for C26-10, and residual FU levels
in C26-B were about one-sixth the values for C26-10.
Thymidylate synthase catalytic activity in untreated C26-10
control tumours was found to be about half the level in C26-B
controls (Po0.001). For both tumours, TS activity decreased
significantly 1 day after 5-FU administration, rebounded to about
twice the control level by day 7, and finally decreased towards
Table 2 5-FU pharmacokinetic parameters and inhibition of TS determined from extracts of C26-B and C26-10 tumours
a
Time C26-B C26-10
Parameter Mean7s.d. n Mean7s.d. Po
FdUMP 2h 138730 6 179742 5
(pmolg
 1 wet wt.) 4h 107722 6 147778 5
24h 22.072.7 4 32715 4
48h 13.371.8 4 46735 4
5-FU 7 days 0.1470.03 4 0.8270.34 4 0.05
(nmolg
 1 wet wt.) 10 days 0.1270.02 4 0.7970.22 4 0.02
5-FU-RNA 2 days 7.4170.30 4 2.2571.55 4 0.01
(pmol 5-FUmg
 1 RNA) 3 days 6.6370.20 4 1.7170.53 4 0.001
7 days 0.2570.025 4 0.4070.01 4 0.001
10 days 0.0670.01 4 0.1670.01 4 0.001
TS catalytic activity Controls 5.7370.41 8 2.8570.20 8 0.001
(nmolh
 1mg
 1 protein) 1 day 0.7270.10 4 1.0970.03 4 0.001
3 days 1.2170.18 4 1.7270.48 4
7 days 9.9670.15 4 5.7370.43 4 0.001
10 days 8.5571.24 4 1.9270.28 4 0.001
FdUMP binding Controls 122733 8 93712 8
(fmolg
 1 wet wt.) 1 day 32.572.3 4 20.371.5 4 0.001
3 days 31.575.4 4 22.673.8 4 0.05
7 days 201744 4 165733 4
10 days 190731 4 145723 4
aTumours were excised at the times shown in column 2, following 5-FU treatment (day 0: bolus i.p., 150mgkg
 1) or were taken from untreated controls with tumours of similar
size. After excision, tumours were immediately frozen in liquid nitrogen. The P values o0.05 are given for comparisons between the two tumour types (two-sided t-tests,
assuming equal variance).
Table 3 Response of C26-B and C26-10 tumours to 5-FU treatment with or without carbogen breathing
Tumour (Group) Treatment
a n TD
b (days) GDF
c WL (%)
d n
C26-B Controls 2.971.1
(1) 5-FU 9 10.2 (6.9, 17.1) 2.52 5.678.4 10
(2) 5-FU+carbogen 11 10.2 (6.9, 19.6) 2.52 11.175.7 11
C26-10 Controls 4.172.6
(3) 5-FU 11 13.3 (9.3, 428) 2.23 11.978.3 13
(4) 5-FU+carbogen 10 428 (9, 428) 45.83 11.173.3 10
aThe Group number corresponds to the labelling in Figure 2.
bTumour doubling time is presented as mean7s.d. for
untreated historical controls or as median (min, max) measured from treatment day 0 (excluding mice withothree
observations). The symbol4indicates that doubling did not occur before the end of the experiment on day 28. One C26-
10 tumour treated with 5-FU and one C26-10 tumour treated with 5-FU+carbogen showed complete remission.
Significance of comparisons (Wilcoxon rank-sum test): (1) vs (3) P¼0.048; (2) vs (4) P¼0.002; (1) vs (2) P¼0.62; (3) vs
(4) p¼0.033.
c Growth delay factor (see Materials and Methods).
dMean weight loss per time point (see Materials and
Methods) (mean7s.d., including mice withothree observations).
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scontrol levels on day 10. The relative inhibition of TS (compared to
controls) at day 1 was significantly higher for C26-B (factor 8) vs
C26-10 (factor 2.6), while the relative degree of overshoot at day 7
was similar.
In untreated controls, the mean number of FdUMP binding sites
in the sensitive C26-10 tumours was 76% of the mean for C26-B
(difference not statistically significant). Following 5-FU treatment,
the number of binding sites for both tumour types decreased by
about a factor of 4 at day 1 and rebounded with the same
overshoot behaviour at day 7 as observed for TS activity. The
number of binding sites for C26-10 relative to C26-B remained at
60–80% over the 10-day time course.
Tumour histology
Histological examinations of six individual untreated tumours of
C26-B and of C26-10 murine colon carcinoma were performed.
Both variants were poorly differentiated adenocarcinoma with less
than 15% necrosis on days 11–12 after implantation, and no clear
differences in histology or vascularisation were observed.
Effect of 5-FU treatment on tumour growth
Normalised growth curves for s.c. C26-B and C26-10 tumours in
Balb/C mice following i.p. bolus 5-FU treatment are shown in
Figure 2, and the parameters doubling time (TD), growth delay
factor (GDF), and weight loss (WL) derived from these data are
shown in Table 3. Note that the two tumour variants have
inherently different growth rates in untreated controls, with the
less sensitive C26-B tumour showing faster growth (TD¼2.9 days)
compared to the more sensitive C26-10 tumour (TD¼4.1 days).
5-Fluorouracil treatment without carbogen led to moderate
regression at day 4 for both tumour types, but growth continued
again after day 7 with C26-B exhibiting the higher growth rate.
Owing to 5-FU, the doubling times calculated from day 0 increased
to 10.2 days (C26-B, group 1 in Figure 2) and 13.3 days (C26-10,
group 3) and were significantly different (P¼0.048), but the
growth delay factors were similar (2.52 vs 2.23).
When carbogen was applied during treatment, there was no
significant change in the initial response of C26-B tumours (group
2: TD, GDF unchanged), but there was a moderate decrease in the
mean growth rate after day 11 for the carbogen group. A
significant effect of carbogen was observed, however, for the 5-
FU-sensitive C26-10 tumours (group 4) with the median doubling
time increasing to 428 days (P¼0.033 vs group 3, P¼0.002 vs
group 2), giving a GDF45.8. Tumour regrowth began only after an
average of 17 days. Following the single bolus 5-FU treatment,
complete tumour remission was observed only for two out of 26
C26-10 tumours (one with and one without carbogen).
The mean percentage weight loss (WL) over the time period
days 0–28 was 6% for the C26-B tumour-bearing animals treated
with 5-FU alone and 12% in the other three groups. These values
were considered to be within acceptable limits.
DISCUSSION
Here, we present the first
19F MRS results (0–2h time course) for
two variants of the C26 tumour line with different sensitivities to 5-
FU, along with biochemical data derived from tissue extracts (time
courses from 2h postdrug to up to 10days). Our
19F MRS results
show that the more sensitive C26-10 tumour exhibits a signifi-
cantly higher conversion of 5-FU to fluoronucleotides (cytotoxic
anabolites) compared to the insensitive, more rapidly growing
C26-B tumour (Cmax and AUC in Table 1). These results support
previous findings that positive therapy response correlates with the
concentration of anabolites achieved in tumour tissue, either
directly or with the aid of modulators (McSheehy et al, 1989, 1992;
Koutcher et al, 1991; Sijens and Ng, 1992; Findlay et al, 1993;
Tausch-Treml et al, 1996; Holland et al, 1997). The broad anabolite
peak observed in Figure 1 represents the complete family of
fluoronucleotides (mono-, di-, triphosphates; oxy- and deoxy
forms) which cannot be further distinguished with in vivo
19F
MRS. Previous studies have shown that the major contributors to
the anabolite peak are probably FUMP, FUDP, FUTP, and FUDP-
hexoses (Lutz and Hull, 1999). The ratio FUTP/FdUMP may be as
high as 50 (Benz and Cadman, 1981; Peters et al, 1986), and the
concentrations of free FdUMP and its ternary complex with TS are
generally o1mM (Washtien, 1984). Thus, these key species cannot
be detected by in vivo
19F MRS. However, the concentration of
FdUMP in C26 tumours (van der Wilt et al, 1992; van Laar et al,
1996b) and in patients (Peters et al, 1993) has been determined by
other methods and was found to be high enough to inhibit TS
effectively.
Table 1 shows that there are no significant differences between
the tumour variants for uptake of 5-FU (Cmax, AUC) or its half-life
(t1/2). Therefore, these parameters cannot account for the higher
anabolite levels observed in C26-10 compared to C26-B. Differ-
ences in catabolism of 5-FU in tumour via dihydropyrimidine
dehydrogenase (DPD) can also be ruled out since DPD was not
detectable in either tumour variant (Visser et al, 1996). Thus, 5-FU
catabolism in C26 tumours is expected to be insignificant, and the
catabolites detected in the spectra of tumour tissue (Figure 1) are
considered to result from uptake from the circulation due to the
high plasma levels generated by the extremely efficient catabolism
(detoxification) of 5-FU in the liver (Grem, 1990). A correlation
between 5-FU catabolites in tumour and levels in plasma and
surrounding tissue (Naser-Hijazi et al, 1991) or levels in kidney
(Lutz et al, 1991) has been demonstrated in other studies. Since
catabolite levels in liver can reach several millimolars following
bolus treatment (5–10 times the levels in tumour), even a 5%
contribution of liver tissue to the sensitive volume detected by a
surface coil can be responsible, at least in part, for the catabolite
signals detected.
100
10
1
R
e
l
a
t
i
v
e
 
t
u
m
o
u
r
 
v
o
l
u
m
e
4 7 11 13 17 20 23 26
Days
(1) C26-B 5-FU
(2) C26-B 5-FU + carbogen
(4) C26-10 5-FU + carbogen
(3) C26-10 5-FU
Figure 2 Normalised growth curves (relative tumour volume:
mean7s.d.) for s.c. implanted colon carcinoma C26-B and C26-10 in
Balb/C mice after i.p. bolus treatment with 150mgkg
 1 5-FU alone (C26-B,
n¼9; C26-10, n¼11) or in combination with 9.5-min carbogen breathing
(C26-B, n¼11; C26-10, n¼10). Two-way ANOVA indicates that
differences between tumour variants are highly significant with or without
carbogen: group 1 vs 3, P¼0.02; group 2 vs 4, P¼0.003. A significant effect
of carbogen was observed only for the more slowly growing, 5-FU-sensitive
C26-10 tumours: group 1 vs 2, P¼0.35; group 3 vs 4, P¼0.03.
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sThus, enhanced anabolic conversion of 5-FU is likely to be
responsible for the higher levels of fluoronucleotides detected by
MRS in C26-10 vs C26-B tumours. Higher activity of uridine
phosphorylase or uridine kinase in C26-10 could result in more
rapid formation of FUMP and subsequent conversion to FUTP,
FdUMP, and FdUTP, which are responsible for the so-called RNA-
and DNA-directed mechanisms of 5-FU cytotoxicity. Both
mechanisms may indeed be active, but their relative importance
may depend on cell phenotype, cell cycle, and other parameters.
Note that despite the higher anabolite levels observed by MRS in
C26-10 tumours, the average degree of growth inhibition or
regression at day 4 was essentially the same for both tumour types
(Figure 2).
Since MRS provides little information on the details of 5-FU
cytotoxicity, the biochemical data of Table 2 are of interest. The
incorporation of FUTP into RNA (structural damage, misreading
of nucleotides) was actually higher in the insensitive C26-B
tumours at days 2 and 3 after therapy. On the other hand, a more
rapid clearance of fluorine from RNA by day 7 was observed for
C26-B (faster growth rate, higher RNA turnover) compared to C26-
10, and both 5-FU-RNA and free 5-FU levels were lower in C26-B
at days 7 and 10. This ability of C26-B tumour cells to clear more
rapidly 5-FU from RNA may contribute to the insensitivity of this
cell line to 5-FU therapy and the return to a normal growth rate
after day 7 (TD¼2.7, Figure 2). In contrast, C26-10 tumours
showed less initial incorporation of 5-FU into RNA but slower
clearance and higher long-term 5-FU levels (days 7 and 10), and
these effects are associated with only a partial recovery in growth
after day 7 (TD¼ca. 6, Figure 2). In spite of this evidence, the
relative importance of RNA-directed cytotoxicity in determining
therapy response in C26 tumours cannot be precisely defined at
this time.
Thymidylate synthase represents a potential target for the DNA-
directed mechanism of fluoropyrimidine chemotherapy (Danen-
berg, 1977). FdUMP produced by intracellular metabolism of 5-FU
in tumours is an analogue of dUMP and blocks de novo dTMP
production by forming a stable covalent ternary complex with TS
and a tetrahydrofolate cofactor, leading to a depletion of dTTP
needed for DNA synthesis. The relatively insensitive C26-B
tumours exhibit a higher growth rate (shorter doubling time)
and higher basal TS catalytic activity (Table 2, controls) compared
to the 5-FU-sensitive C26-10 tumours (van Laar et al, 1996a). In
addition, the pools of reduced folates are smaller in C26-B and
could limit the achievable degree of TS inhibition (van der Wilt
et al, 2001). We found that following 5-FU treatment, C26-B
tumours generated somewhat lower levels of FdUMP compared to
C26-10 (not statistically significant), but for both tumours the
concentrations of FdUMP after 2h were about 1000-fold higher
than the number of FdUMP binding sites found in controls. Both
types of tumour exhibited a significant reduction in available
binding sites and inhibition of TS at days 1 and 3 following 5-FU
treatment, and the degree of inhibition was in fact higher for C26-B
compared to C26-10. Both tumours exhibited a rebound in FdUMP
binding sites and TS activity at days 7 and 10 to levels even higher
than controls, indicating induced synthesis of TS. However, the
rebound in TS activity in C26-B was larger and longer lasting,
analogous to the more efficient clearance of 5-FU from RNA (see
above).
Translational regulation of key enzymes has been implicated as
a possible mechanism for the development of drug resistance
(reviewed by Schmitz et al, 2001), and it has been shown that
overexpression of TS in breast and colon carcinoma cell lines
results in reduced sensitivity to 5-FU treatment in vitro (Chu et al,
1991a). It has been shown that TS controls (suppresses) its own
synthesis (autoregulation) by binding to an untranslated region of
TS mRNA, and that FdUMP leads to an induction of TS by
deregulation (derepression) of TS synthesis (Chu et al, 1991b). It
was proposed that this ligand-mediated induction of TS occurs
because the ternary complex TS-FdUMP-tetrahydrofolate exhibits
weaker binding to TS mRNA and is, therefore, inefficient in
suppressing TS synthesis. More recently, Kitchens et al (1999) have
provided experimental evidence with colon tumour cell lines that
the autoregulation model may not be the universal explanation for
ligand-mediated induction of TS. In particular, a three-base
modification of TS mRNA which abolished TS binding did not
interfere with drug-mediated TS induction. It was shown that
ligand binding increased the stability of TS towards proteolytical
degradation and increased the intracellular half-life of TS several
fold, that is by an amount consistent with the observed induction.
Thus, it was reasoned that enhanced TS concentrations were not a
result of enhanced protein synthesis, but rather decreased
degradation due to the stability of the inhibitory ternary complex.
Since the complex sequesters FdUMP, it may serve to reduce
intracellular levels of FdUMP and sensitivity to 5-FU (Kitchens
et al, 1999).
Both the translation and stability mechanisms discussed above
may, in fact, operate in the cell lines investigated in our study
(Peters et al, 2002). The information at hand (rebound in TS
catalytic activity and available FdUMP binding sites above control
levels) does provide evidence that is more consistent with
enhanced TS synthesis rather than the stability model. In any
event, all of the results presented here suggest that the lower
sensitivity of C26-B to 5-FU treatment may not only be due to the
lower levels of MRS-detectable fluoronucleotides but perhaps more
importantly due to the ability of this cell line to recover more
effectively from both RNA- and DNA-directed cytotoxicity via
more efficient clearance of 5-FU from RNA and greater TS
induction, respectively.
As to the effect of carbogen on 5-FU treatment, we previously
found increased levels of 5-FU and its metabolites as a result of
carbogen breathing in a different murine colon tumour model
(Kamm et al, 2000). However, in the current study, carbogen
breathing for 9.5min during 5-FU administration did not
significantly affect the MRS-detectable aspects of 5-FU metabolism
in either C26 tumour variant. In terms of tumour growth, there was
no effect on TD or GDF for C26-B tumours and only a minor
decrease in the regrowth rate (TD¼3.5 from day 7, Figure 2).
However, a dramatic effect of carbogen was observed for the
sensitive C26-10 tumours: growth inhibition out to day 17
(Figure 2) with a significant increase in the parameters TD and
GDF (Table 3). Since carbogen did not increase the MRS-detected
levels of 5-FU or fluoronucleotides at 2h postdrug administration
in the C26 tumours studied, the reason for the prolonged growth
delay with C26-10 remains unclear at this time. Certainly, it will be
of interest to investigate the biochemical parameters of Table 2 as a
function of carbogen exposure.
We note that it has been demonstrated for a rat tumour model
(Lemaire et al, 1998) that good energy status (NTP/Pi ratio) prior
to therapy (presumably improved by carbogen) and a high level of
fluoronucleotides produced following a 5-FU bolus were associated
with tumour regression. However, we do not have appropriate
31P-
MRS data to address this point for C26. It is known that the effect
of carbogen may depend on tumour characteristics such as type,
size, vascularisation, perfusion, and pH (Rodrigues et al, 1997), but
we do not yet have detailed information concerning oxygenation
or pH status for the C26 tumours. Furthermore, it may be
necessary to extend the carbogen breathing period to account for
the resorption delay associated with i.p. vs i.v. drug administration
(Griffiths et al, 2001).
In conclusion, we provide quantitative evidence for differences
between two variants of the C26 murine colon carcinoma in terms of
in vivo 5-FU uptake and anabolic conversion as well as recovery from
treatment via clearance of 5-FU from RNA and induction of TS. These
differences are consistent with and probably responsible for the
observed differences in sensitivity to 5-FU treatment. These findings
concerning possible mechanisms or sources of drug resistance may be
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sof immediate clinical relevance since cancer patients exhibit a wide
range of sensitivity to fluoropyrimidine therapy.
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